This is a summary of the European public assessment report (EPAR) for Reconcile. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Reconcile.
For practical information about using Reconcile, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Reconcile : EPAR - Summary for the public (PDF/73.53 KB)
First published: 15/07/2008
Last updated: 19/10/2016
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Forte Healthcare Limited
|Date of issue of marketing authorisation valid throughout the European Union||
Forte Healthcare Ltd
16/06/2021 Reconcile - EMEA/V/C/000133 - IA/0038
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
As an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate behaviours (vocalisation and inappropriate defecation and / or urination) and only in combination with behavioural-modification techniques.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 5-7 October 202108/10/2021